Oncology Billing — Built for Your Practice
Oncology billing operates at a scale where billing errors are measured in thousands of dollars per patient per visit. A single mAb infusion visit for a patient on bevacizumab generates: a drug charge that can reach $8,000–$15,000 for the J-code alone, plus chemotherapy infusion administration codes, hydration infusion add-ons, pre-medications, and an E&M code for the oncology visit. Getting the drug administration hierarchy wrong on that claim — or missing the concurrent pre-medication codes — costs more than a month of primary care billing revenue.
Our oncology billing team has worked with community oncology practices, hospital-based infusion centers, and multi-site cancer groups. We know the drug administration code hierarchy (you cannot bill two primary infusion codes on the same date; one is always primary and the others are sequential or concurrent add-ons). We know which biosimilars have their own Q-codes versus using the reference product J-code. And we know the clinical trial billing boundary — where insurance ends and the sponsor begins — in ways that keep practices out of federal False Claims Act territory.
Why Oncology Billing Is Complex
The specific billing challenges in oncology that separate expert billing from average billing:
- Drug administration code hierarchy — the most resource-intensive service is always the primary code. For infusions: 96413 (chemotherapy, first hour) is primary, 96415 (each additional hour) adds on. When a second chemotherapy agent is infused concurrently: 96417 (sequential chemo infusion, first hour) + 96415 (each additional hour). When a non-chemo drug is infused concurrently with chemo: 96367 (concurrent infusion, each additional drug). Each day's claims must follow this hierarchy — two primary infusion codes on the same date triggers automatic denial
- J-code and Q-code drug billing accuracy — each drug has a specific HCPCS code and a per-unit dosing definition. Bevacizumab is J9035 at 10mg units; a 400mg dose = 40 units. Billing 4 units (off by a decimal) means billing for 40mg. Billing the reference product J-code (J9035) when a biosimilar bevacizumab (Q5119 for Mvasi) was administered creates both a billing accuracy issue and a payer mismatch
- Biosimilar vs. reference biologic — biosimilars are therapeutically interchangeable versions of reference biologics. FDA-approved biosimilars have specific Q-codes that differ from the originator's J-code. Some payers require Q-codes; others accept either. Defaulting to the reference product J-code when a biosimilar was used can cause claim mismatches or, worse, give the impression of billing for a more expensive drug than was actually administered
- Clinical trial billing separation — routine care costs (standard of care services that would occur regardless of trial participation) are billable to insurance. Trial-required items (additional labs, scans, or procedures required only because of the study protocol) must be billed to the trial sponsor. Billing trial-required items to insurance is a compliance violation under OIG guidance — and a federal False Claims Act risk when the payer is Medicare or Medicaid
- Hydration and supportive care billing — pre-medications, anti-nausea drugs, hydration before nephrotoxic agents, and growth factors are all separately billable as concurrent infusion add-ons. A well-coded chemotherapy visit captures all concurrent infusions, not just the primary chemotherapy drug
- ✓ Specialty-specific denial prevention
- ✓ Certified coders trained on your CPT codes
- ✓ Payer-specific rules for Oncology
Common Oncology CPT Codes We Handle
Our Oncology billing team is trained on every major procedure code — from E&M visits to specialty-specific procedures — ensuring accurate coding and maximum reimbursement.
Not seeing your code? We handle all Oncology CPT, HCPCS, and ICD-10 codes.
Top Oncology Claim Denial Reasons — and How We Eliminate Them
Most Oncology denials are preventable. Our team knows exactly what to look for before submission.
❌ Two Primary Infusion Codes on Same Date — Administration Hierarchy Violation
When a patient receives two different chemotherapy agents on the same date — say, carboplatin and paclitaxel — one is the primary infusion (96413) and the other is a sequential infusion (96417). Billing 96413 twice is wrong; the claims processing system reads it as a duplicate service and denies the second charge. This error is common in practices where nursing staff enter "chemotherapy administration" charges for each drug without understanding the administration hierarchy, and it appears on every multi-drug treatment day.
✓ Our Fix
Our oncology billing system builds the administration code set from the nursing infusion record — specifically the order of infusion start times and the nature of each agent. The most resource-intensive service becomes the primary code; all subsequent agents are coded as sequential (96417) or concurrent (96367) add-ons. We review the infusion record for every multi-agent day before submission.
❌ J-Code Units Calculated Incorrectly
Drug HCPCS codes have a unit size defined in the code descriptor: J9035 is bevacizumab per 10mg. A 600mg dose = 60 units of J9035, not 6 units and not 1 unit. A biller who enters "1 unit" defaults the entire drug charge to $X for 10mg — underbilling by 59 units. At current Medicare allowable rates for bevacizumab, a single unit calculation error on a 600mg dose represents $1,200–$1,800 in lost revenue on that one drug charge, per visit.
✓ Our Fix
Our drug billing workflow ties J-code unit calculation directly to the nursing administration record and pharmacy dispensing record. For every drug charge, we verify: the drug name, the administered dose in milligrams (or other units), and the HCPCS code unit size. Drug charges are cross-referenced with pharmacy dispensing data before any claim that includes a J-code is submitted.
❌ Reference Product J-Code Billed When Biosimilar Was Administered
When the pharmacy dispenses Mvasi (biosimilar bevacizumab) but the billing system defaults to J9035 (reference product Avastin), the claim reflects Avastin was given. Most of the time, payers adjudicate either code at the same rate — but the claim now says the practice used a more expensive drug than was actually used. When this pattern appears on audit, it creates documentation-to-billing mismatches that auditors treat as potentially fraudulent upcoding, even if the financial impact was zero.
✓ Our Fix
We maintain a current biosimilar-to-Q-code mapping that is updated whenever the FDA approves a new biosimilar. The pharmacy dispensing record specifies the exact product dispensed — we code from the actual product, never the reference standard. Every oncology client gets a quarterly biosimilar update report showing which agents have approved biosimilars and their correct billing codes.
❌ Clinical Trial Required Services Billed to Medicare or Medicaid
When a Medicare patient is enrolled in a clinical trial, the National Coverage Determination (NCD 310.1) defines what routine care costs are billable to Medicare. Protocol-required items (additional research labs, extra imaging scans, study drug, protocol monitoring visits that would not occur in standard care) must be billed to the trial sponsor. Practices that bill all services to Medicare — including trial-required items — are committing fraud under the False Claims Act when protocol-required items are billed to the government payer.
✓ Our Fix
Before enrolling any Medicare or Medicaid patient in a clinical trial, we review the protocol to identify trial-required items and establish a billing segregation map. Every patient enrolled in an active trial gets a billing flag in our system that requires review against the protocol itemization before their claims are submitted. Trial-required items are routed to the sponsor; routine care costs go to Medicare. This protocol is reviewed with the PI and research coordinator at the start of every new trial.
Everything Included with ZenoMedix RCM Oncology Billing
- Chemotherapy drug administration hierarchy — correct primary/sequential/concurrent coding
- J-code drug charge accuracy with per-unit dose verification from pharmacy records
- Biosimilar Q-code billing — FDA-current biosimilar-to-code mapping maintained quarterly
- Clinical trial billing compliance — routine care vs. trial-required item segregation
- High-cost oncologic drug prior authorization with clinical documentation support
- Infusion suite revenue optimization: hydration, supportive care, and pre-med add-ons
- Port placement (36561), port access (96522), and catheter management billing
- 98%+ collection rate for community oncology and cancer center practices
Complete Revenue Cycle for Oncology Practices
"Our Oncology practice increased collections by 30% in just 90 days. Phenomenal team."— Practice Manager, Oncology Group
Oncology Billing Available in All 50 States
From California to New York, our Oncology billing specialists understand your state's Medicaid program, payer mix, and compliance requirements.
Find Your State →Oncology Billing FAQ
When three drugs are administered, one is primary, and the others depend on timing and overlap. The most resource-intensive is the primary service. If all three are chemotherapy: (1) First agent — 96413 (primary chemo, first hour) + 96415 for each additional hour; (2) Second agent started sequentially (after first finishes) — 96417 (sequential chemo, first hour) + 96415 additional hours; (3) Third agent also sequential — another 96417 + 96415. If pre-medication or anti-nausea drug is infused concurrently: that's 96365 for first non-chemo infusion (if primary), or 96367 for each concurrent drug running simultaneously with the primary. The hierarchy is determined by the nursing infusion record — start times, overlap, and drug identity.
Authorization for drugs like pembrolizumab, nivolumab, trastuzumab, and CAR-T therapies requires comprehensive clinical submissions: pathology with biomarker results (PD-L1 expression, MSI status, HER2 status), staging documentation, prior therapy history, and evidence-based clinical guideline citations (NCCN, ASCO). We maintain indication-specific auth templates for every major oncologic agent, updated when FDA expands indications or when NCCN guidelines change. Auth requests are submitted with the complete package — not a one-page clinical summary — which reduces initial denial rates substantially. When denials occur, we file peer-to-peer requests within 48 hours.
Under the Medicare Clinical Trial Policy (NCD 310.1), Medicare covers routine costs of care for qualifying clinical trials. Routine costs include: services that would be provided regardless of trial participation, services for management of complications arising from participation, and services needed for reasonable and necessary care. NOT covered by Medicare (must bill to sponsor): investigational items, items provided solely for data collection, and services that exceed standard care requirements. Our approach is to document the billing segregation in writing before the first patient is enrolled, map every service in the trial protocol to either "routine care" or "trial-required," and review every trial patient's claims against that map before submission.
In-office infusion billing (POS 11) generates the full professional fee including the administration service — the practice is paid for both the drug and the administration work. Hospital outpatient department (HOPD) billing (POS 22) generates the professional fee at the facility rate (lower than non-facility), while the hospital separately bills the facility fee. When the same drug is administered in both settings, the physician's billing must reflect the correct POS and rate for each location. We maintain separate billing configurations for each practice location and verify POS accuracy before every claim — a $300–$800 per-claim revenue difference between the two settings.
Oral oncologic drugs prescribed and administered in the office use HCPCS codes billed on the medical claim. Oral drugs prescribed for patient self-administration (take-home) typically flow through specialty pharmacy and are billed under the pharmacy benefit, not the medical benefit. We handle in-office oral drug billing (e.g., temozolomide dispensed in the office) using the correct HCPCS codes with appropriate quantity documentation. For take-home prescriptions, we coordinate with your specialty pharmacy partner to ensure the transition from infusion to oral is documented in the medical record and that authorizations are in place before the first oral prescription.
Oncology Billing Results — By the Numbers
See How Much More Your Oncology Practice Can Collect
- ✓Specialty-specific coding analysis
- ✓Denial pattern review
- ✓Payer mix assessment
- ✓Revenue recovery estimate